Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity
Hongyan Liu(Queensland University of Technology), Qing Zhang(South China University of Technology), Mengmeng Lü(Xuzhou Medical College), Junnian Zheng(Xuzhou Medical College), Chao Huang(Xuzhou Medical College), Xiaohuan Wei(Xuzhou Medical College), Zhen Li(Tongji Hospital), Gang Wang(Jiangsu University), Shishuo Sun(Xuzhou Medical College), Xiaokang Zhang, Xiaoge Gao(Xuzhou Medical College)
Cited by 20
Related Papers
Cancer drug delivery in the nano era: An overview and perspectives
|Oncology Reports|2017|399
Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment
|Oncotarget|2018|217
DNA damage response – A double-edged sword in cancer prevention and cancer therapy
|Cancer Letters|2014|189
Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
|Journal of Immunology Research|2018|152
HAb18G/CD147 Functions in Invasion and Metastasis of Hepatocellular Carcinoma
|Molecular Cancer Research|2007|148